Martina Brueckmann

Head of Global Development Cardiovascular

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Martina Brueckmann is the Head of Global Development Cardiovascular at Boehringer Ingelheim International GmbH in Germany. Her research focuses on innovative treatments for cardiovascular diseases, particularly in heart failure and obesity, as evidenced by her recent publications on empagliflozin and its effects, as well as clinical trials aimed at improving patient outcomes. She has contributed significantly to understanding the implications of various treatments across different patient demographics.

Articles (11)

Year:

2025

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

Peter D. Schellinger

GERMANY

View details

Jennifer Green

Duke University

UNITED STATES

View details

Lucas Lauder

Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes

GERMANY

View details

JP Ferreira

Université de Lorraine

FRANCE

View details

J. Donald Easton

Professor Emeritus

University of California, San Francisco

UNITED STATES

View details

Milton Packer

Baylor University Medical Center

UNITED STATES

View details

Stefan Anker

Charité

GERMANY

View details

Ralph L. Sacco

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Martina Brueckmann

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)

Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial

Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure

Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE‐SPECT ESUS Trial

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial

Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial

Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials

Collaborators (8)

Peter D. Schellinger

Jennifer Green

Lucas Lauder

JP Ferreira

J. Donald Easton

Milton Packer

Stefan Anker

Ralph L. Sacco

Make your next move.